Old Web
English
Sign In
Acemap
>
Paper
>
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
2019
Valentina Shakhnovich
Bernd Meibohm
Amy S. Rosenberg
Andrzej M. Kierzek
Rachel Hasenkamp
Ryan S. Funk
Craig J. Thalhauser
Piet H. van der Graaf
Yow‐Ming C. Wang
Lora Hamuro
Keywords:
Family medicine
Diabetes mellitus
Clinical Practice
Medicine
Drug development
Intensive care medicine
Immunogenicity
Correction
Source
Cite
Save
Machine Reading By IdeaReader
10
References
6
Citations
NaN
KQI
[]